VivoSense Inc has been awarded an NIH/NCI Phase 1 contract to develop software enabling data integration from wearable sensors for cancer patients. The contract will result in the development of the VivoSense Cancer Health Informatics Platform as the leading wearable sensor agnostic cloud platform for cancer research and clinical care. TrialSite’s ‘Investor Watch’ introduces this Newport Coast, CA-based startup.
TrialSite breaks down this news, the value proposition and the potential.
What is the problem?
Although cancer remains one of the most devastating diseases, the past decade has brought enormous progress, particularly in the field of immunotherapy. However, these breakthrough cancer therapeutics don’t benefit all patients equally. Wearables have created an opportunity to gain more insight into the factors contributing to this outcome. The unprecedented amount of patient-specific, real-world data from wearable sensors opens the door to rethink how clinical trials can advance personalized treatment strategies.
What is the underlying premise to this effort?
Patient monitoring and the precise delivery of cancer care improves outcomes and the management of symptoms and side-effects. With robust wearable sensor solutions, care providers will have the ability to passively and continuously monitor multiple behavioral and biological parameters that can be used to adjust and optimize treatment strategies throughout care. As patients with cancer live longer, it is vitally important to understand and develop treatment regimens that maintain patient quality of life.
Goal of this initiative
The company, VivoSense, seeks to translate real-world data into actionable information in order to advance earlier diagnosis and precise treatment options in cancer patients. Their position: this is a huge step forward for cancer research. Hence they will use the funds from the NIH/NCI to engage key opinion leaders at every step and build an end-to-end data informatic platform explicitly designed for cancer research and care options.
Kate Lyden, PhD, serves as Principal Investigator for this contract and is also VivoSense’ VP of Science and Research. Ms. Lyden commented in the company’s press release, “Wearable sensors and digital biomarkers have the potential to revolutionize cancer research and care. Our ten years of wearable sensor analytics experience ideally positions VivoSense to deliver on this award with an innovative cancer-specific analytics.”
Phase 1 of this project has been funded 100% with federal funds in the amount of $392,519 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under contract no. 75N91020C00058.
Who is VivoSense?
Founded in 2010 by Dudley Tabakin and Lance Myers, VivoSense, Orange County, CA-based VivoSense positions itself as a leader in data analysis consulting and software, specializing in wearable sensor physiological monitoring solutions for research and clinical trials. On its LinkedIn page, it describes that it’s the first analytics company to develop novel biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. Several of these studies were in rare disease indications have purportedly have reached the open-label phase of development at a large pharmaceutical company client.
Founder and CEO Dudley Tabakin is a Orange County motion capture expert, having spent just about twenty years in this line of business. He earned his undergraduate (Engineering) University of the Witwatersrand as well as his MSc in Biomedical Engineering at University of Cape Town, both in South Africa. Interestingly, the other co-founder, Lance Myers, left the company in 2017 to work for Google’s Verily Life Sciences.
TrialSite Investor Watch POV
Although it doesn’t appear that this small, privately-held venture has grown that fast (still under 20 employees in year 10) they may just be on to something. According to Pitchbook, they have raised $2 million in Angel funding. Both founders have considerable technical pedigree and Dr. Lyden’s background is impressive. The NIH grant isn’t that big but it could be an indicator they could be pursuing an important space. With at least one large pharmaceutical client this startup has potential: the market space involving biomedical wearable sensors and associated software becomes ever more important..
Investor Watch would have liked to hear more specifics of the project in the press release.
Call to Action: The company’s Dr. Kate Lyden is interested in connecting with partners (oncology investigators, drug developers and providers). She can be contacted at [email protected].